Navigation Links
NIH awards $7.8 million for innovative HIV vaccine approaches
Date:8/21/2012

The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, has awarded 14 grants totaling $7.8 million in first-year funding for basic research to identify new approaches for designing a safe and effective HIV vaccine. The grants were awarded under the Innovation for HIV Vaccine Discovery (IHVD) initiative, which is expected to receive up to $34.8 million over the next four years.

"Recent discoveries about the basic biology of HIV and how the virus adapts to its host have provided useful information and new opportunities to guide vaccine development," said NIAID Director Anthony S. Fauci, M.D. "These grants are designed to build on that information and stimulate discovery of new ways to design a robust vaccine that prevents acquisition and establishment of latent infection."

The 14 IHVD grant recipient organizations include:

Altravax Inc. (Sunnyvale, Calif.)
Principal Investigator: Robert Whalen, DSc.
Project title: Germline-Specific Immunogens for the Induction of Neutralizing Antibodies to HIV-1.
The initial award, supported by grant number 1R01AI10270601, is for $597,816 for fiscal year 2012.

Catholic University of America (Washington, D.C.)
Principal Investigator: Venigalla Rao, Ph.D.
Project title: Potent Phage T4-Derived V2 Immunogens as HIV Vaccines.
The initial award, supported by grant number 1R01AI10272501, is for $413,787 for fiscal year 2012.

Dartmouth College (Hanover, N.H.)
Principal Investigator: Margaret Ackerman, Ph.D.
Project title: Applying High-Performance Protein Engineering Tools to HIV Immunogen Design.
The initial award, supported by grant number 1R01AI10269101, is for $479,437 for fiscal year 2012.

Duke University (Durham, N.C.)
Principal Investigator: Herman Staats, Ph.D.
Project title: Mucosal Vaccination to Protect Against HIV-1 Infection at Mucosal Sites.
The initial award, supported by grant number 1R01AI10274701, is for $492,072 for fiscal year 2012.

Harvard Medical School (Boston)
Principal Investigator: Amitinder Kaur, M.D.
Project title: Natural Killer T Cells as Modulators of AIDS Vaccine Efficacy.
The initial award, supported by grant number 1R01AI10269301, is for $846,896 for fiscal year 2012.

Massachusetts General Hospital (Boston)
Principal Investigator: Galit Alter, Ph.D.
Project title: Tuning Fc-Effector Functions of HIV-Specific Antibodies.
The initial award, supported by grant number 1R01AI10266001, is for $609,875 for fiscal year 2012.

NYU Langone Medical Center (New York City)
Principal Investigator: Catarina Hioe, Ph.D.
Project title: Contributions of Anti-V2 Antibodies in Protection Against HIV.
The initial award, supported by grant number 1R01AI10274001, is for $579,543 for fiscal year 2012.

University of California (Irvine)
Principal Investigator: Donald Forthal, M.D.
Project title: The Impact of Antibody and pH on Female-to-Male SIV Infection.
The initial award, supported by grant number 1R01AI10271501, is for $718,324 for fiscal year 2012.

University of Maryland (Baltimore)
Principal Investigator: Charles Pauza, Ph.D.
Project title: Neonatal Fc-Receptor-Targeted Mucosal HIV Vaccine.
The initial award, supported by grant number 1R01AI10268001, is for $779,175 for fiscal year 2012.

University of Medicine and Dentistry of New Jersey (Newark)
Principal Investigator: Abraham Pinter, Ph.D.
Project title: Optimizing Protective Vaccine Targets in the V1/V2 Domain of HIV-1 gp120.
The initial award, supported by grant number 1R01AI10271801, is for $566,739 for fiscal year 2012.

University of Minnesota (Minneapolis)
Principal Investigator: Ashley Haase, M.D.
Project title: Vaccine Design to Concentrate Protective Antibodies at the Mucosal Border.
The initial award, supported by grant number 1R01AI10262501, is for $843,856 for fiscal year 2012.

University of North Carolina (Chapel Hill)
Principal Investigator: Nikolay Dokholyan, Ph.D.
Project title: Immunogen Design to Target Carbohydrate-Occluded Epitopes on the HIV envelope.
The initial award, supported by grant number 1R01AI10273201, is for $514,331 for fiscal year 2012.

University of Rochester (Rochester, N.Y.)
Principal Investigator: Mark Dumont, Ph.D.
Project title: Yeast Genetic Approach to Enhance the Immunogenicity of HIV Envelope Glycoprotein.
The initial award, supported by grant number 1R01AI10273001, is for $386,250 for fiscal year 2012.

University of Texas at El Paso
Principal Investigator: June Kan-Mitchell, Ph.D.
Project title: Effector and Regulatory Activities of HLA-E-restricted HIV-specific CD8 T Cells.
The initial award, supported by grant number 1R01AI10266301, is for $531,600 for fiscal year 2012.


'/>"/>
Contact: Tasheema Prince
princeta@niaid.nih.gov
301-402-1663
NIH/National Institute of Allergy and Infectious Diseases
Source:Eurekalert

Related medicine news :

1. National Hartford Centers of Gerontological Nursing Excellence awards new fellows, scholars
2. ASTRO awards 5 research grants
3. State stem cell research funding agency awards $20 million to UCI, StemCells Inc.
4. Prevention of HIV spread focus of NIDAs 2012 Avant-Garde Awards
5. Klerman/Freedman Awards
6. Damon Runyon Cancer Research Foundation grants fellowship awards to 21 top young scientists
7. AOSSM presents annual research awards
8. U-Ms Taubman Institute awards inaugural $100,000 translational medical research prize
9. Standard Process Inc.’s Marketing Team Wins Six Awards
10. NIH awards $6.1 million grant to GUMC to establish Center of Excellence for Health Disparities
11. Stanford Woods Institute for the Environment announces 2012 Environmental Venture Project awards
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... CA (PRWEB) , ... June 25, 2016 , ... As ... with Magna Cum Laude and his M.D from the David Geffen School of Medicine ... and returned to Los Angeles to complete his fellowship in hematology/oncology at the UCLA-Olive ...
(Date:6/25/2016)... ... June 25, 2016 , ... On Friday, June 10, ... Bronze Wellness at Work award to iHire in recognition of their exemplary accomplishments in ... the 7th annual Maryland Workplace Health & Wellness Symposium at the BWI Marriott in ...
(Date:6/24/2016)... Angeles, CA (PRWEB) , ... June 24, 2016 , ... ... surgery procedures that most people are unfamiliar with. The article goes on to state ... procedures, but also many of these less common operations such as calf and cheek ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... June 19, ... the dangers associated with chronic pain and the benefits of holistic treatments, Serenity ... who are suffering with Sickle Cell Disease. , Sickle Cell Disease (SCD) is a ...
(Date:6/24/2016)... ... June 24, 2016 , ... The Pulmonary Hypertension Association ... it will receive two significant new grants to support its work to advance ... 25th anniversary by recognizing patients, medical professionals and scientists for their work in ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... Research and Markets has announced the addition of ... report to their offering. ... The World Market for Companion Diagnostics covers the world market ... the report includes the following: , World ... Region (N. America, EU, ROW), 2015-2020 , World IVD ...
(Date:6/24/2016)... Mass. , June 24, 2016   Pulmatrix, ... pharmaceutical company developing innovative inhaled drugs, announced today that ... Russell Investments reconstituted its comprehensive set of ... "This is an important milestone for Pulmatrix," ... will increase shareholder awareness of our progress in developing ...
(Date:6/24/2016)... , June 24, 2016  Arkis BioSciences, a ... invasive and more durable cerebrospinal fluid treatments, today ... The Series-A funding is led by Innova Memphis, ... and other private investors.  Arkis, new financing will ... and the market release of its in-licensed Endexo® ...
Breaking Medicine Technology: